Minli joined Erasca as vice president of pharmaceutical development and operations bringing more than 20 years of experience in drug development from discovery candidate selection through registration and launch. Prior to Erasca, she was one of the first 20 employees at Myovant Sciences, serving as vice president of pharmaceutical operations and development, where she built the CMC organization and oversaw the CMC activities that helped support the successful development and approval of Orgovyx® and the combination product, Myfembree®, for multiple indications. Previously, Minli was head of small molecule technical operations at Medivation, and her team’s work enabled the registration and approval of Talzenna®. She also built and led the small molecule pharmaceutics team at Genentech, supporting the small molecule research and development projects, including Erivedge® and Cotellic®. She also worked at Bristol Myers Squibb and DuPont Merck in roles of increasing responsibility.
Minli has a Ph.D. in pharmaceutical chemistry and a B.S. in chemistry, both from the University of Kansas.